Sees FY24 revenue $2.55B-$2.65B, consensus $2.58B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMRX:
- Is AMRX a Buy, Before Earnings?
- Amneal in licensing agreement with Zambon Biotech for IPX203
- Amneal provides complete response resubmission to FDA for IPX203 NDA
- Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
- Amneal Pharmaceuticals price target raised to $8 from $6 at Barclays
